Biotech Medics Ne
BioTech Medics, Inc. operates as a medical-based holding company. The company operates medical therapeutic laser centers that treat various pain ailments affecting the muscles, nerves, and bones, as well as arthritis. It also offers SHBAN, an antiseptic hand and body sanitizer. In addition, the company develops and sells nutraceutical products, such as BioBody Balance, a liquid vitamin concentrat… Read more
Biotech Medics Ne (BMCS) - Net Assets
Latest net assets as of March 2025: $99.56 Million USD
Based on the latest financial reports, Biotech Medics Ne (BMCS) has net assets worth $99.56 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($100.00 Million) and total liabilities ($441.14K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $99.56 Million |
| % of Total Assets | 99.56% |
| Annual Growth Rate | 32.79% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 84.47 |
Biotech Medics Ne - Net Assets Trend (2008–2024)
This chart illustrates how Biotech Medics Ne's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biotech Medics Ne (2008–2024)
The table below shows the annual net assets of Biotech Medics Ne from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $99.57 Million | 0.00% |
| 2023-12-31 | $99.57 Million | +43.11% |
| 2022-12-31 | $69.58 Million | -0.14% |
| 2021-12-31 | $69.67 Million | +37403.09% |
| 2020-12-31 | $-186.78K | -331.54% |
| 2016-12-31 | $-43.28K | -104.47% |
| 2015-12-31 | $968.05K | -68.36% |
| 2011-12-31 | $3.06 Million | +2.12% |
| 2010-12-31 | $3.00 Million | +181.42% |
| 2008-12-31 | $1.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biotech Medics Ne's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 171574400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $205.36K | 0.21% |
| Other Components | $101.08 Million | 101.52% |
| Total Equity | $99.57 Million | 100.00% |
Biotech Medics Ne Competitors by Market Cap
The table below lists competitors of Biotech Medics Ne ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SEMARIS LTD
SEM:SEMA
|
$129.96 |
|
Augmentum Fintech PLC
LSE:AUGM
|
$130.09 |
|
BLUELIFE LIMITED
SEM:BLL
|
$130.12 |
|
Innoveren Scientific Inc.
PINK:IVRN
|
$130.13 |
|
PICIC Insurance Ltd
KAR:PIL
|
$129.52 |
|
Worldsec Ltd
LSE:WSL
|
$129.43 |
|
CVR Medical Corp
STU:B3BN
|
$128.97 |
|
European Resources Limited
AU:ERE
|
$128.93 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotech Medics Ne's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 99,570,693 to 99,565,783, a change of -4,910 (-0.0%).
- Net loss of 2,919 reduced equity.
- Other comprehensive income increased equity by 202,356.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.92K | -0.0% |
| Other Comprehensive Income | $202.36K | +0.2% |
| Other Changes | $-204.35K | -0.21% |
| Total Change | $- | 0.00% |
Book Value vs Market Value Analysis
This analysis compares Biotech Medics Ne's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $0.00 | $0.01 | x |
| 2011-12-31 | $0.00 | $0.01 | x |
| 2015-12-31 | $0.00 | $0.01 | x |
| 2016-12-31 | $0.00 | $0.01 | x |
| 2017-12-31 | $0.00 | $0.01 | x |
| 2018-12-31 | $0.00 | $0.01 | x |
| 2019-12-31 | $0.00 | $0.01 | x |
| 2020-12-31 | $0.00 | $0.01 | x |
| 2021-12-31 | $0.34 | $0.01 | x |
| 2022-12-31 | $0.34 | $0.01 | x |
| 2023-12-31 | $0.49 | $0.01 | x |
| 2024-12-31 | $0.49 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotech Medics Ne utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.00x
- Recent ROE (-0.00%) is above the historical average (-13.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -17.19% | -38.39% | 0.06x | 7.26x | $-289.51K |
| 2010 | 0.00% | 0.00% | 0.00x | 1.52x | $-299.65K |
| 2011 | -19.73% | -128.51% | 0.09x | 1.66x | $-909.73K |
| 2015 | -121.15% | 0.00% | 0.00x | 1.05x | $-1.27 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.01 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $2.15K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-50.69K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-90.99K |
| 2021 | -0.46% | 0.00% | 0.00x | 1.00x | $-7.29 Million |
| 2022 | -0.17% | 0.00% | 0.00x | 1.01x | $-7.07 Million |
| 2023 | -0.01% | 0.00% | 0.00x | 1.00x | $-9.96 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 1.00x | $-9.96 Million |
Industry Comparison
This section compares Biotech Medics Ne's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotech Medics Ne (BMCS) | $99.56 Million | -17.19% | 0.00x | $129.82 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |